See more : A. Libental Holdings Ltd (LBTL.TA) Income Statement Analysis – Financial Results
Complete financial analysis of Theratechnologies Inc. (THTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Theratechnologies Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- iBX Group, Inc. (IBXG) Income Statement Analysis – Financial Results
- John Wood Group PLC (WDGJF) Income Statement Analysis – Financial Results
- Wolters Kluwer N.V. (WTKWY) Income Statement Analysis – Financial Results
- Sumitomo Densetsu Co.,Ltd. (1949.T) Income Statement Analysis – Financial Results
- Saudi Paper Manufacturing Company (2300.SR) Income Statement Analysis – Financial Results
Theratechnologies Inc. (THTX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.theratech.com
About Theratechnologies Inc.
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 81.76M | 80.06M | 69.82M | 66.05M | 63.22M | 44.05M | 33.23M | 27.60M | 22.55M | 5.90M | 7.13M | 13.66M |
| Cost of Revenue | 19.64M | 26.28M | 23.26M | 26.90M | 26.08M | 14.68M | 17.15M | 10.14M | 6.70M | 7.07M | 10.46M | 11.47M |
| Gross Profit | 62.13M | 53.78M | 46.56M | 39.15M | 37.14M | 29.38M | 16.07M | 17.47M | 15.85M | -1.17M | -3.33M | 2.18M |
| Gross Profit Ratio | 75.99% | 67.17% | 66.69% | 59.27% | 58.75% | 66.68% | 48.37% | 63.28% | 70.29% | -19.90% | -46.72% | 15.99% |
| Research & Development | 30.37M | 36.94M | 28.27M | 18.02M | 10.84M | 7.77M | 9.19M | 5.65M | 4.11M | 4.95M | 7.09M | 7.08M |
| General & Administrative | 15.62M | 17.36M | 14.62M | 12.23M | 8.33M | 5.83M | 4.51M | 3.57M | 2.99M | 4.00M | 3.55M | 5.50M |
| Selling & Marketing | 26.77M | 39.39M | 28.91M | 26.86M | 26.48M | 21.69M | 20.17M | 10.86M | 9.66M | 6.10M | 236.05K | 857.67K |
| SG&A | 42.39M | 56.75M | 43.53M | 39.09M | 34.81M | 25.02M | 24.67M | 14.54M | 12.74M | 10.10M | 3.84M | 6.36M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 850.00K | 22.07M |
| Operating Expenses | 72.76M | 93.69M | 71.80M | 57.11M | 45.65M | 32.79M | -30.64M | -16.76M | -14.28M | -8.21M | -901.69K | -16.97M |
| Cost & Expenses | 92.39M | 119.97M | 95.06M | 84.01M | 71.73M | 47.47M | -13.48M | -6.63M | -7.58M | -1.14M | 9.56M | -5.50M |
| Interest Income | 0.00 | 316.00K | 195.00K | 299.00K | 1.10M | 285.00K | 261.99K | 77.44K | 30.76K | 173.52K | 429.60K | 762.04K |
| Interest Expense | 10.55M | 6.50M | 5.66M | 5.36M | 4.99M | 2.53M | 1.07M | 1.44M | 1.87M | 1.05M | 12.25K | 23.12K |
| Depreciation & Amortization | 3.30M | 12.03M | 8.58M | 8.84M | 7.50M | 4.14M | 1.55M | 1.57M | 1.44M | 1.00M | 114.25K | 567.75K |
| EBITDA | -10.31M | -27.87M | -17.16M | -9.18M | 28.01K | 731.32K | -11.68M | 3.79M | 4.55M | -6.68M | -7.06M | -3.60M |
| EBITDA Ratio | -12.61% | -33.92% | -23.38% | -13.89% | 0.06% | 1.66% | -21.24% | 16.31% | 20.17% | -113.15% | -98.94% | -26.39% |
| Operating Income | -10.63M | -39.91M | -25.24M | -17.96M | -8.51M | -3.41M | -8.60M | 2.93M | 3.11M | -7.68M | -7.17M | -4.17M |
| Operating Income Ratio | -13.00% | -49.85% | -36.14% | -27.19% | -13.47% | -7.75% | -25.89% | 10.62% | 13.79% | -130.11% | -100.54% | -30.54% |
| Total Other Income/Expenses | -12.91M | -6.89M | -6.43M | -4.69M | -3.98M | -2.56M | -5.72M | -2.15M | -1.50M | -1.53M | 3.37M | -9.86M |
| Income Before Tax | -23.54M | -46.79M | -31.66M | -22.65M | -12.50M | -5.77M | -14.30M | 781.10K | 1.61M | -9.21M | -3.80M | -14.03M |
| Income Before Tax Ratio | -28.79% | -58.45% | -45.35% | -34.29% | -19.77% | -13.11% | -43.04% | 2.83% | 7.12% | -156.12% | -53.34% | -102.71% |
| Income Tax Expense | 421.00K | 443.00K | 63.00K | 16.00K | 4.99M | -1.25M | -2.17K | 475.81K | 426.91K | 27.17K | 24.55K | 5.03K |
| Net Income | -23.96M | -47.24M | -31.73M | -22.67M | -12.50M | -4.52M | -14.30M | 305.29K | 1.18M | -9.24M | -3.83M | -14.03M |
| Net Income Ratio | -29.30% | -59.00% | -45.44% | -34.32% | -19.77% | -10.27% | -43.04% | 1.11% | 5.23% | -156.58% | -53.69% | -102.75% |
| EPS | -0.91 | -1.98 | -1.37 | -1.18 | -0.65 | -0.24 | -0.78 | 0.02 | 0.06 | -0.61 | -0.25 | -0.93 |
| EPS Diluted | -0.91 | -1.98 | -1.37 | -1.18 | -0.65 | -0.24 | -0.78 | 0.02 | 0.07 | -0.61 | -0.25 | -0.92 |
| Weighted Avg Shares Out | 26.33M | 23.81M | 23.09M | 19.25M | 19.23M | 18.99M | 18.37M | 16.45M | 19.64M | 15.25M | 15.25M | 15.15M |
| Weighted Avg Shares Out (Dil) | 26.33M | 23.81M | 23.09M | 19.25M | 19.23M | 18.99M | 18.37M | 16.65M | 15.79M | 15.25M | 15.25M | 15.25M |
Theratechnologies (THTX) Upgraded to Buy: What Does It Mean for the Stock?
Theratechnologies (THTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
MONTREAL, April 15, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company has mailed its 2024 management proxy...
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
MONTREAL, April 11, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company's President and CEO, Paul Lévesque will...
Theratechnologies Inc. (THTX) Q1 2024 Earnings Call Transcript
Theratechnologies Inc. (NASDAQ:THTX ) Q1 2024 Earnings Conference Call April 10, 2024 8:30 AM ET Company Participants Julie Schneiderman - Senior Director, Communications & Corporate Affairs Paul Levesque - President & CEO Philippe Dubuc - SVP & CFO Christian Marsolais...
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
MONTREAL, April 10, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the first quarter...
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
MONTREAL, April 08, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that highlight the versatility and flexibility of...
Theratechnologies Appoints Elina Tea to its Board of Directors
MONTREAL, April 05, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Elina Tea, Chief Financial Officer at...
Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update
MONTREAL, April 03, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a...
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform
MONTREAL, March 28, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced two posters will be presented at the American Association...
Theratechnologies Announces Update on its Preclinical Oncology Research Program
Company continues to shift to commercial focus as it seeks partners to advance R&D MONTREAL, March 22, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization...
Source: https://incomestatements.info
Category: Stock Reports